(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Portfolio Pulse from Benzinga Insights
Biomarin Pharmaceutical's short interest has decreased by 3.3%, with 6.65 million shares sold short, representing 3.52% of its float. This is lower than the peer group average of 4.16%. The decrease in short interest may indicate a more bullish sentiment towards the stock.
September 10, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biomarin Pharmaceutical's short interest has decreased by 3.3%, with 6.65 million shares sold short, representing 3.52% of its float. This is lower than the peer group average of 4.16%. The decrease in short interest may indicate a more bullish sentiment towards the stock.
The decrease in short interest suggests that investors are less bearish on Biomarin Pharmaceutical, which could lead to a positive impact on the stock price. The short interest is also below the peer average, further indicating a relatively more bullish sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100